Logos Global Management’s Structure Therapeutics GPCR Stock Holding History

Logos Global Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.8M	Hold	500,000	–	–	1.16%	29
2026 Q1	$24.1M	Sell	500,000 -100,000	-17%	-$6.84M	1.2%	29
2025 Q4	$41.7M	Sell	600,000 -250,000	-29%	-$10.2M	2.52%	10
2025 Q3	$23.8M	Hold	850,000	–	–	2.13%	19
2025 Q2	$17.6M	Buy	850,000 +425,000	+100%	+$9.34M	1.95%	19
2025 Q1	$7.36M	Sell	425,000 -275,000	-39%	-$6.74M	1.31%	23
2024 Q4	$19M	Sell	700,000 -550,000	-44%	-$19.5M	2.22%	16
2024 Q3	$54.9M	Buy	1,250,000 +150,000	+14%	+$5.8M	5.92%	2
2024 Q2	$43.2M	Buy	1,100,000 +379,942	+53%	+$15.6M	3.47%	8
2024 Q1	$30.9M	Sell	720,058 -350,000	-33%	-$14.8M	2.5%	13
2023 Q4	$43.6M	Buy	1,070,058 +570,058	+114%	+$32.7M	4.07%	9
2023 Q3	$25.2M	Buy	500,000 +100,000	+25%	+$3.22M	3.36%	8
2023 Q2	$16.6M	Buy	400,000 +50,000	+14%	+$1.4M	2.26%	16
2023 Q1	$8.33M	Buy	+350,000	New	+$8.22M	1.19%	31

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Logos Global Management's GPCR Position: Q2 2026 in Review

Logos Global Management held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 500,000 shares worth $26.8M. The position accounts for 1.16% of the portfolio, ranked #29.

Logos Global Management first reported a position in GPCR in Q1 2023 and has held it in 14 quarters since. The position peaked at $54.9M in Q3 2024. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Logos Global Management held 500,000 shares of Structure Therapeutics worth $26.8M as of Q2 2026.
Logos Global Management left its Structure Therapeutics share count unchanged in Q2 2026.
Structure Therapeutics made up 1.16% of Logos Global Management's portfolio in Q2 2026, its #29 holding.
Logos Global Management first reported a position in Structure Therapeutics in Q1 2023 and has held it in 14 quarters since.
Logos Global Management's Structure Therapeutics position peaked at $54.9M in Q3 2024.
192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.